Weijun Gu

11PUBLICATIONS
12CO-AUTHORS
Immunogenetics (incl. genetic immunology)Predictive and prognostic markersCell physiologyToxicology (incl. clinical toxicology)Nutritional epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 20, 2026
Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study.

|Feb 09, 2026
miR-221/222 Facilitate Pituitary Adenoma Progression Via PHACTR4 Downregulation.

Wenjing Dong, Shiju Yan, Lingyun Song

|Oct 14, 2025
Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D study.

Weijun Gu, Xiaohong Wu, Minlu Zhang

|Apr 19, 2025
Long-term cardiometabolic outcomes of primary bilateral macronodular adrenal hyperplasia.

Huixin Zhou, Peng Zhang, Yaqi Yin

|Mar 12, 2025
Efficacy and safety of once-weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial.

Weijun Gu, Yibing Lu, Xinhua Ye

|Aug 13, 2024
Remnant cholesterol is more positively related to diabetes, prediabetes, and insulin resistance than conventional lipid parameters and lipid ratios: A multicenter, large sample survey.

Binqi Li, Yang Liu, Xin Zhou

Pageof 2

Frequent Collaborators

8 joint publications

Yiming Mu

3 joint publications

Binqi Li

2 joint publications

Yang Liu

2 joint publications

Zuojie Luo